The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tatva Chintan Pharma Chem Ltd
NSE:TATVA
|
IN |
|
Mitsui O.S.K. Lines Ltd
OTC:MSLOF
|
JP |
|
C
|
China Minsheng Banking Corp Ltd
XMUN:GHFH
|
CN |
|
G
|
Grupo Aeroportuario del Centro Norte SAB De CV
XMUN:G7A
|
MX |
|
K
|
Kamada Ltd
TASE:KMDA
|
IL |
|
F
|
Franklin Resources Inc
XMUN:FRK
|
US |
|
R
|
Resources Connection Inc
SWB:RCO
|
US |
|
R
|
Royal Bank of Canada
NYSE:RY
|
CA |
|
S
|
Silver Hammer Mining Corp
CNSX:HAMR
|
CA |
|
INOVIQ Ltd
ASX:IIQ
|
AU |
|
V
|
Vardhman Textiles Ltd
BSE:502986
|
IN |
|
Ryder System Inc
NYSE:R
|
US |
|
Hospital Mater Dei SA
BOVESPA:MATD3
|
BR |
|
Prysmian SpA
F:AEU
|
IT |
|
F
|
Fox E-Mobility AG
DUS:CT4
|
DE |
|
D
|
Dow Inc
SWB:2OY
|
US |
|
I
|
IAMGOLD Corp
F:IAL
|
CA |
|
A
|
AUK Corp
KRX:017900
|
KR |
|
S
|
SLOMAN NEPTUN Schiffahrts-AG
XHAM:NEP
|
DE |
|
I
|
Ionis Pharmaceuticals Inc
F:ISI
|
US |
|
Shikoku Electric Power Co Inc
TSE:9507
|
JP |
|
B
|
BASF SE
BET:BASF
|
DE |
|
Rosslyn Data Technologies PLC
LSE:RDT
|
UK |
Tatva Chintan Pharma Chem Ltd (TATVA)’s 12-month stock price forecast through October 2027 has a consensus target of ₹1 519.8, implying 13% downside. The forecast is based on price targets from 7 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
TATVA is 1 519.8 INR with a low forecast of 843.35 INR and a high forecast of 2 052.75 INR.
Over the last 6 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 26%.
Over the last 6 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 36%.
Over the last 6 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 3 years is 50%.
Over the last 6 years, the compound annual growth rate for Pre-Tax Income has been 3%. The projected CAGR for the next 3 years is 50%.
Over the last 6 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 3 years is 51%.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more